MADRIGAL PHARMACEUTICALS INC

Only three of Madrigal Pharmaceuticals' 25 institutional holders reported any reduction this quarter, and the largest — Eastern Bank, cutting 24.4% of its shares (86 to 65) — moved just $10,116, a rounding error next to the scale of buying elsewhere. That buying is dominated by one fund: Assenagon Asset Management, flagged quasi_passive, grew its position more than sevenfold, from 16,033 to 124,214 shares, a genuine $58.1 million increase that now makes it 84.6% of the stock's $78.8 million in tracked institutional value. Because of Assenagon's classification, that surge likely reflects index-weighting mechanics — possibly tied to the stock's market-cap growth — rather than a discretionary conviction call, even though the dollar figure dwarfs everything else in the holder table.